Tasigna



Indications and Reactions:

Role Indications Reactions
Primary
Chronic Myeloid Leukaemia 68.0%
Hypertension 7.3%
Prophylaxis 4.8%
Gastrointestinal Stromal Tumour 3.7%
Diabetes Mellitus 2.2%
Pain 1.8%
Acute Lymphocytic Leukaemia 1.4%
Coronary Artery Disease 1.0%
Leukaemia 1.0%
Depression 1.0%
Hypercholesterolaemia 1.0%
Hypothyroidism 1.0%
Neoplasm Malignant 0.9%
Constipation 0.9%
Nausea 0.7%
Hyperlipidaemia 0.7%
Insomnia 0.6%
Dyspepsia 0.6%
Hyperuricaemia 0.6%
Atrial Fibrillation 0.6%
Death 19.1%
Electrocardiogram Qt Prolonged 9.6%
Rash 8.7%
Myocardial Infarction 6.7%
Vomiting 6.6%
Thrombocytopenia 6.0%
Weight Decreased 3.8%
White Blood Cell Count Decreased 3.7%
Nausea 3.6%
Pruritus 3.6%
Pyrexia 3.6%
Neoplasm Malignant 3.1%
Platelet Count Decreased 3.1%
Dyspnoea 2.8%
Fatigue 2.8%
Pneumonia 2.8%
Cerebrovascular Accident 2.7%
Pancreatitis 2.7%
Pain 2.6%
Headache 2.5%
Secondary
Chronic Myeloid Leukaemia 52.7%
Prophylaxis 10.9%
Hypertension 8.1%
Diabetes Mellitus 4.6%
Gastrointestinal Stromal Tumour 3.0%
Constipation 2.6%
Pain 2.1%
Coronary Artery Disease 2.1%
Rheumatoid Arthritis 1.9%
Hyperlipidaemia 1.6%
Insomnia 1.3%
Hypothyroidism 1.2%
Acute Myeloid Leukaemia 1.2%
Dyspepsia 1.2%
Atrial Fibrillation 1.1%
Hyperuricaemia 1.0%
Dry Eye 0.9%
Nasopharyngitis 0.9%
Depression 0.8%
Nausea 0.8%
White Blood Cell Count Decreased 11.2%
Electrocardiogram Qt Prolonged 10.7%
Thrombocytopenia 8.4%
Rash 7.1%
Platelet Count Decreased 6.4%
Vascular Graft 6.0%
Pyrexia 5.4%
Vomiting 5.3%
Pulmonary Oedema 3.7%
Weight Increased 3.5%
Coronary Artery Disease 3.4%
Weight Decreased 3.4%
White Blood Cell Count Increased 3.4%
Stent Placement 3.3%
Ventricular Extrasystoles 3.3%
Fatigue 3.2%
Malaise 3.1%
Myocardial Infarction 3.1%
Uterine Cancer 3.0%
Incorrect Dose Administered 2.9%
Concomitant
Product Used For Unknown Indication 28.2%
Chronic Myeloid Leukaemia 27.5%
Leukaemia 5.3%
Prophylaxis 4.6%
Prophylaxis Against Graft Versus Host Disease 4.6%
Acute Lymphocytic Leukaemia 3.8%
Antiviral Prophylaxis 3.1%
Bone Marrow Conditioning Regimen 2.3%
Hypertension 2.3%
Nervous System Disorder 2.3%
Paroxysmal Nocturnal Haemoglobinuria 2.3%
Antifungal Prophylaxis 1.5%
Arthritis 1.5%
Drug Intolerance 1.5%
Fungal Infection 1.5%
Graft Versus Host Disease In Intestine 1.5%
Hiv Infection 1.5%
Hyperuricaemia 1.5%
Hypothyroidism 1.5%
Immunosuppressant Drug Therapy 1.5%
Dyspnoea 6.7%
Fatigue 6.7%
Myalgia 6.7%
Myocardial Infarction 6.7%
Off Label Use 6.7%
Pleural Effusion 6.7%
Polypectomy 6.7%
Rash 6.7%
Tachycardia 6.7%
White Blood Cell Count Increased 6.7%
Arachnoiditis 3.3%
Balance Disorder 3.3%
Basal Cell Carcinoma 3.3%
Blood Creatinine Increased 3.3%
Blood Urine Present 3.3%
Cardiac Failure Congestive 3.3%
Chest Pain 3.3%
Chronic Myeloid Leukaemia 3.3%
Convulsion 3.3%
Decreased Appetite 3.3%
Interacting
Chronic Myeloid Leukaemia 49.4%
Arrhythmia 7.4%
Gastrooesophageal Reflux Disease 4.9%
Hypertension 4.9%
Diabetes Mellitus 3.7%
Acute Lymphocytic Leukaemia 2.5%
Atrial Fibrillation 2.5%
Chromosome Analysis Abnormal 2.5%
Epididymitis 2.5%
Hypercholesterolaemia 2.5%
Hyperuricaemia 2.5%
Neuropathy Peripheral 2.5%
Oesophagitis 2.5%
Product Used For Unknown Indication 2.5%
Antacid Therapy 1.2%
Blood Pressure 1.2%
Myeloproliferative Disorder 1.2%
Oedema 1.2%
Parkinson's Disease 1.2%
Pneumonia Bacterial 1.2%
Drug Interaction 25.8%
Electrocardiogram Qt Prolonged 12.9%
Asthenia 6.5%
Atrial Flutter 6.5%
Myalgia 6.5%
Cardiac Failure 3.2%
Convulsion 3.2%
Coronary Artery Disease 3.2%
Fluid Retention 3.2%
Gingivitis 3.2%
Headache 3.2%
Nasal Congestion 3.2%
Nausea 3.2%
Oedema Peripheral 3.2%
Pancreatitis 3.2%
Sepsis 3.2%
Therapeutic Response Decreased 3.2%
Visual Acuity Reduced 3.2%